These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2307090)

  • 1. Effect of a new lente insulin on diabetics.
    Ohneda A; Nihei J; Sasaki M
    Diabetes Res Clin Pract; 1990 Jan; 8(2):101-7. PubMed ID: 2307090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial.
    Blackshear PJ; Roussell AM; Cohen AM; Nathan DM
    Diabetes Care; 1989; 12(7):455-63. PubMed ID: 2667926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of monocomponent insulin and commercial insulin preparations on insulin requiring diabetics (author's transl)].
    Nakashima Y; Oyama H; Tenku A; Matsumura S; Nishida S
    Radioisotopes; 1977 Mar; 26(3):158-62. PubMed ID: 578932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW; Teller WM; Heinze E
    Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human ultralente insulin.
    Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
    Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.
    McMahon M; Marsh HM; Rizza RA
    Diabetes; 1989 Mar; 38(3):291-303. PubMed ID: 2492963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate-acting insulin preparations: NPH and lente.
    Deckert T
    Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lente insulin for treatment of diabetes mellitus in 12 cats.
    Bertoy EH; Nelson RW; Feldman EC
    J Am Vet Med Assoc; 1995 Jun; 206(11):1729-31. PubMed ID: 7782245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
    Peacock I; Tattersall RB
    Br Med J (Clin Res Ed); 1984 Jun; 288(6435):1956-9. PubMed ID: 6428619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic qualities of a lente preparation of swine insulins manufactured by Pharmachem].
    Andreev D; Bozadzhieva E; Pampulov L; Penchev I; Uzunova B
    Vutr Boles; 1977; 16(6):59-66. PubMed ID: 341532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of early-morning hyperglycemia in type 1 diabetics with amorphous zinc insulin (Semilente) at bedtime.
    Strasser D; Nützi E; Spinas GA; Berger W
    Horm Res; 1993; 39(5-6):173-8. PubMed ID: 8314199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative evaluation of the effectiveness of insulin preparations "Lente GP" and "Insulong" in type 1 diabetes mellitus].
    Kudriakova SV; Belovanova IM; Romanovskaia GA; Kasymov UA
    Sov Med; 1991; (9):75-7. PubMed ID: 1798933
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
    Buturovic BA; Ristic LB; Narancic AM
    Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes.
    Okuno Y; Sakaguchi K; Komada H; Hashimoto N; Hirota Y; Nakamura T; Ogawa W; Seino S
    Kobe J Med Sci; 2013 Apr; 59(2):E44-53. PubMed ID: 23756662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.